Application of Irinotecan based on simulation screening as AIBP inhibitor
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NANTONG UNIVERSITY
- Publication Date
- 2020-03-20
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
Technical field
[0001] The invention belongs to the technical field of medical research, and specifically relates to the application of Irinotecan as an AIBP inhibitor based on molecular docking and molecular dynamics simulation screening and a simulation screening method. Background technique
[0002] Apo A-1 binding protein (AIBP) is a secreted protein that can bind to apoA-1. In recent years, a large number of studies have found that AIBP is related to the occurrence and development of cardiovascular diseases. Studies have confirmed that AIBP is highly expressed in myocardial tissue in patients with ischemic heart disease; AIBP can inhibit the occurrence and development of lipid metabolism disorders such as familial mixed hyperlipidemia; AIBP in the platelets of patients with deep vein thrombosis increases and inhibits thrombosis; AIBP can also regulate the cholesterol levels of human umbilical vein endothelial cells and zebrafish embryos, and inhibit vascular endothelial gro...